Study patients with onset or worsening of GVHD after B-cell transfer
| Patient-ID . | B-cell dose (×106/kg b.w.) . | GVHD with organ involvement before B-cell transfer and after B-cell transfer . | Onset GVHD (days after B-cell transfer) . | Outcome of GVHD . | |
|---|---|---|---|---|---|
| BT01 | 0.5 | Mild de novo cGVHD skin (1)∗, liver (1) | Worsening to moderate cGVHD skin (1), liver (2), oral (1) | 83 | Resolved 127 d after B-cell transfer on budesonide therapy and topical steroids |
| BT10 | 1.0 | Resolved acute GVHD, skin (3), grade 2† | Recurrence of acute GVHD, skin (1), grade 1 | 7 | Resolved 14 d after B-cell transfer on topical steroids |
| BT12 | 2.0 | Mild cGVHD, skin (1), liver (1) | Worsening to moderate cGVHD eyes (2), liver (2) | 89 | Resolved 108 d after B-cell transfer on budesonide and steroid eye drops |
| BT20 | 3.0 | Resolved acute GVHD, skin (2), lower GI (1), grade 2 | Recurrence of acute GVHD, skin (2), grade 1 | 63 | Resolved 98 d after B-cell transfer on prednisolone 0.5 mg/kg b.w. |
| Patient-ID . | B-cell dose (×106/kg b.w.) . | GVHD with organ involvement before B-cell transfer and after B-cell transfer . | Onset GVHD (days after B-cell transfer) . | Outcome of GVHD . | |
|---|---|---|---|---|---|
| BT01 | 0.5 | Mild de novo cGVHD skin (1)∗, liver (1) | Worsening to moderate cGVHD skin (1), liver (2), oral (1) | 83 | Resolved 127 d after B-cell transfer on budesonide therapy and topical steroids |
| BT10 | 1.0 | Resolved acute GVHD, skin (3), grade 2† | Recurrence of acute GVHD, skin (1), grade 1 | 7 | Resolved 14 d after B-cell transfer on topical steroids |
| BT12 | 2.0 | Mild cGVHD, skin (1), liver (1) | Worsening to moderate cGVHD eyes (2), liver (2) | 89 | Resolved 108 d after B-cell transfer on budesonide and steroid eye drops |
| BT20 | 3.0 | Resolved acute GVHD, skin (2), lower GI (1), grade 2 | Recurrence of acute GVHD, skin (2), grade 1 | 63 | Resolved 98 d after B-cell transfer on prednisolone 0.5 mg/kg b.w. |